A vaccine for chlamydia has now passed initial safety tests, meaning that it can now enter human trials; the first of its’ kind to do so, the BBC reports.

If the vaccine is successful, the vaccine may be the best way to eliminate the common disease. Chlamydia is Australia’s most common STDs; a report from the Australian Institute of Health and Welfare said that the rate of infection in 2017 was 379 cases for every 100,000 Australians.

One of the main challenges of treating Chlamydia is that it is a ‘silent’ disease; symptoms are discreet, and many people do not realise that they have the disease. Another is that even after antibiotics treat the disease, you can come into contact with the disease and be infected again.

Chlamydia is most common in under-25s, since that age group tends to go through more partners. The testing period for the vaccine will take some time, likely several years, and practicing safe sex by using a condom remains the best choice in the meantime.

The trial is currently being undertaken by researchers from the Imperial College London, and is comparing the results to the effects of a placebo jab. After one of the two formulas tested stood out, the researchers moved to the next phase of testing.

One of the investigators, Professor Robin Shattock, said “The findings are encouraging as they show the vaccine is safe and produces the type of immune response that could potentially protect against chlamydia.”

“The next step is to take the vaccine forward to further trials, but until that’s done, we won’t know whether it is truly protective or not.”


If you have Chlamydia, it is important to get it tested and treated. Speak with your doctor/GP to find out what’s best for you.